Anavex Life Sciences Corp (AVXL)
4.05
-0.15
(-3.57%)
USD |
NASDAQ |
Jun 25, 16:00
4.05
0.00 (0.00%)
After-Hours: 20:00
Anavex Life Sciences Research and Development Expense (Annual): 43.72M for Sept. 30, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| September 30, 2023 | 43.72M |
| September 30, 2022 | 37.92M |
| September 30, 2021 | 32.98M |
| September 30, 2020 | 25.23M |
| September 30, 2019 | 22.26M |
| September 30, 2018 | 13.34M |
| September 30, 2017 | 10.67M |
| September 30, 2016 | 7.254M |
| September 30, 2015 | 2.272M |
| Date | Value |
|---|---|
| September 30, 2014 | 0.7324M |
| September 30, 2013 | 0.2638M |
| September 30, 2012 | 2.654M |
| September 30, 2011 | 2.597M |
| September 30, 2010 | 2.729M |
| September 30, 2009 | 2.140M |
| September 30, 2008 | 1.480M |
| September 30, 2007 | 0.9597M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
22.26M
Minimum
2019
43.72M
Maximum
2023
32.42M
Average
32.98M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Ventyx Biosciences Inc | 175.77M |
| Checkpoint Therapeutics Inc | 43.57M |
| Biogen Inc | 2.462B |
| Amicus Therapeutics Inc | 152.38M |
| InfuSystems Holdings Inc | -- |